My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Gilead Sciences (NQ:GILD)

151.40 +0.28 (+0.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

51 52 Next >

Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal ↗

January 29, 2024

HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.

Via Benzinga

Behind the Scenes of Gilead Sciences's Latest Options Trends ↗

January 25, 2024

Via Benzinga

Despite its impressive fundamentals, NASDAQ:GILD remains undervalued. ↗

January 25, 2024

When you look at GILEAD SCIENCES INC (NASDAQ:GILD), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer' ↗

January 24, 2024

FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list.

Via Benzinga

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today ↗

January 23, 2024

Via Benzinga

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗

January 23, 2024

In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.

Via Benzinga

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

January 12, 2024

Via Benzinga

NASDAQ:GILD is probably undervalued for the fundamentals it is displaying. ↗

January 04, 2024

GILEAD SCIENCES INC (NASDAQ:GILD) is an undervalued gem with solid fundamentals.

Via Chartmill

7 Speculative Stocks to Double Your Money THIS Year ↗

January 22, 2024

Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.

Via InvestorPlace

Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024 ↗

January 22, 2024

Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.

Via Talk Markets

Why Gilead Sciences Stock Got Mashed on Monday ↗

January 22, 2024

A late-stage trial of an otherwise successful cancer drug failed to produce the desired results.

Via The Motley Fool

S&P 500, Dow Extend All-Time Highs: 'It's A Lot Of Fun For Stock Investors While It Lasts,' Wall Street Veteran Says ↗

January 22, 2024

Stock market continues upward trend, with all major indexes reaching record highs. Wall Street veteran Ed Yardeni outlines three possible scenarios.

Via Benzinga

Topics Stocks

(GILD) - Analyzing Gilead Sciences's Short Interest ↗

January 03, 2024

Via Benzinga

Dow Gains Over 100 Points; Archer-Daniels-Midland Shares Plunge ↗

January 22, 2024

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.27% to 37,967.81 while the NASDAQ rose 0.31% to 15,358.70. The...

Via Benzinga

Topics Stocks

S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday? ↗

January 22, 2024

US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,...

Via Benzinga

Topics Stocks

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 22, 2024

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 22, 2024

Via Benzinga

Crude Oil Surges Over 2%; US Leading Economic Index Falls In December ↗

January 22, 2024

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Monday. The Dow traded up 0.41% to 38,018.23 while the NASDAQ rose 0.30% to 15,356.67. The S&P...

Via Benzinga

Topics Stocks

Why Is HIV Drug Giant Gilead Stock Falling Monday? ↗

January 22, 2024

Gilead's Phase 3 EVOKE-01 study on Trodelvy in metastatic non-small cell lung cancer didn't meet overall survival endpoint. Despite numerical OS improvement, further exploration is planned.

Via Benzinga

Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test ↗

January 22, 2024

The company had hoped Trodelvy would extend overall survival for patients with a form of lung cancer.

Via Investor's Business Daily

EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker ↗

January 18, 2024

The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says.

Via Benzinga

AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades' ↗

January 18, 2024

On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc.

Via Benzinga

AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains ↗

January 11, 2024

AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.

Via Benzinga

Gilead’s Quiet Revolution: Is GILD the Next Big Stock to Soar? ↗

January 10, 2024

While Wall Street obsesses over weight-loss drugs, Gilead Sciences is working on life-saving treatments and GILD stock looks ready to rally.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 10, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 08, 2024

Via Benzinga

Nasdaq 100 Snaps Longest Negative Streak In 14 Months As Tech Stocks Find Relief On Mixed Data ↗

January 05, 2024

The Nasdaq 100 ended the first week of 2024 on a positive note, ending a five-session losing streak, despite volatile trading and conflicting economic data.

Via Benzinga

This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns ↗

January 03, 2024

BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely...

Via Benzinga

Nasdaq 100 Alert: 7 Undervalued Tech Stocks Ready to Rocket in 2024 ↗

January 03, 2024

Despite the gains of last year there are still many undervalued tech stocks on the Nasdaq 100 waiting to explode higher in 2024

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

51 52 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.